Leveragen

What Leveragen does

Leveragen is a privately held biotechnology company founded in 2017 and headquartered in Woburn, Massachusetts (Greater Boston area). The company develops next-generation in vivo antibody discovery platforms built on CRISPR gene editing, synthetic biology, and chromosome engineering. Its core offering is the Singularity Suite of genetically engineered mouse models that exclusively produce heavy-chain antibodies from complete human VH repertoires integrated into the mouse Igh locus, supplemented by the Universality Suite (common light-chain antibodies for bispecific/multi-specific formats) and the Infinity Suite (conventional full-length antibodies). These platforms are reinforced by a sequence-first discovery stack that includes the LeVoyager bioinformatics tool, next-generation sequencing repertoire analysis, next-generation phage display, droplet microfluidic single-cell screening, and proprietary one-step CRISPR knockout genetics that bypasses multi-generational breeding.

Leveragen operates a B2B platform-and-services business model targeting pharmaceutical and biotechnology customers across therapeutic antibody, diagnostic, reagent, and animal health applications. Revenue is generated through four engagement structures: platform licensing of the Singularity Suite mice, fee-for-service integrated discovery (immunization, repertoire capture, phage display, NGS-guided enrichment, recombinant expression, developability assessment), milestone- and royalty-bearing license and co-development agreements, and approved-CRO channels. The company has signed multiple enterprise partnerships across 2024-2026, including a multi-target agreement with Moderna, a multi-target commercial license with 92Bio, collaborations with Moonlight Bio, Cell Signaling Technology, Propeller Bio (which also made a strategic investment), DPBIO, and Antibody Solutions, and most recently a 2026 collaboration with Daiichi Sankyo.

The company is led by founder and CEO Dr. Weisheng V. Chen (formerly Founding Scientist and Head of Genetic Models at Kallyope), supported by ~14 named scientific and operational staff and three high-profile scientific advisors (Drs. Zhijian Lu, Charles Zuker, Tom Maniatis). IP protection includes issued Japan Patent No. JP7799706 covering core Singularity Platform innovations, with corresponding applications pending in the US, China, Europe, Canada, and Australia. Revenue figures are not publicly disclosed.

Name

Leveragen

Legal name

Leveragen, Inc.

Website

https://leveragen.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Leveragen is a Boston-area biotech that builds genetically engineered mouse platforms (Singularity Suite) for in vivo discovery of single-domain, common light-chain, and conventional antibodies, licensing these platforms and providing integrated discovery services to pharmaceutical and biotechnology partners.

Ownership category

akta.pro rank

Product category

Biotechnology Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Antibody discovery platforms
• Genetic engineering services
• Transgenic mouse models
• Single-domain antibodies
• Biologics therapeutics

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel

Revenue model

1. Platform Licensing: Licensing of proprietary Singularity Suite antibody mouse platforms under research, option, and commercial terms. Partners gain access to platform for antibody discovery programs.
2. Integrated Discovery Services: Fee-for-service engagements spanning immunization, repertoire capture, phage display, NGS-guided enrichment analysis, recombinant expression, and early developability assessment. Can be standalone services or combined with platform licensing.
3. Milestone and Royalty Payments: Collaborations include upfront payments, research funding, development/regulatory/commercial milestones, and tiered royalties on global sales. Multi-target research, option and license agreements with Moderna.
4. Co-development Arrangements: Joint development partnerships with flexible commercial terms including milestone-based, royalty-bearing, or milestone- and royalty-free structures tailored to partner strategy and development stage.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Leveragen develops and licenses proprietary genetically engineered mouse platforms (Singularity Suite, Universality Suite, Infinity Suite) that produce fully human single-domain, common light chain, and conventional antibodies for therapeutic discovery. The company also provides integrated antibody discovery services covering immunization, repertoire capture, phage display, NGS-guided analysis, recombinant expression, and developability assessment, sold as standalone engagements or bundled with platform licensing.

Product overview

Leveragen is a platform biotechnology company offering a suite of differentiated in vivo antibody discovery platforms. The core portfolio includes the Singularity Suite (genetically engineered mice for single-domain antibody discovery), the Universality Suite (common light chain antibody mice), and the Infinity Suite (conventional full-length antibody platforms). These platforms are supported by LeVoyager, a proprietary data analysis tool, and complemented by integrated discovery services including genetic engineering, antibody mouse model licensing, and full discovery workflow services. The platforms enable diverse biologic modalities including multispecific antibodies, ADCs, CAR-T therapies, mRNA-encoded antibodies, and cell therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Singularity Sapiens Mouse Flagship genetically engineered mouse platform that exclusively generates heavy chain antibodies from the complete human VH repertoire integrated into the mouse Igh locus, enabling discovery of fully human single-domain antibodies with high diversity, affinity, stability, solubility, modularity, and functionality. Licensed to pharmaceutical and biotech partners for therapeutic antibody discovery.
• Singularity Suite Collection of genetically engineered mouse models capable of generating exclusively single-domain antibodies from VH repertoires of humans, mice, and companion animals (human VH, human Vκ, alpaca VHH, shark VNAR, dog VH, cat VH, and mouse VH), supporting diverse therapeutic, diagnostic, and animal health applications.
• Universality Suite Series of common light chain antibody mice, each expressing a fully human common light chain derived from an FDA-approved therapeutic antibody, crossed with humanized Igh allele mice to generate diverse common light chain antibodies for bispecific and multi-specific antibody development.
• Infinity Suite Proprietary platforms for discovery of conventional full-length antibodies across human and selected non-human species, maintaining intact antibody architectures with native heavy- and light-chain pairing for normal immune selection, affinity maturation, and broad epitope coverage.
• Genetic Engineering Services Advanced genetic engineering services for complex, high-fidelity genome modification including direct and conditional knockouts, point mutations, single- and multi-allelic knock-ins, locus humanization, and next-generation genetics technology enabling one-step generation of knockouts without multi-generational breeding. Sold to research and pharmaceutical organizations needing custom animal models.
• Antibody Mouse Model Licensing Licensing of proprietary Singularity Suite antibody mouse platforms developed exclusively for single-domain antibody discovery, available to partners under research, option, and commercial terms.
• Integrated Antibody Discovery Services Comprehensive antibody discovery services spanning immunization, repertoire capture, phage display, NGS-guided enrichment analysis with family scanning and hit expansion, recombinant expression, and early developability assessment, available as standalone services or combined with platform licensing for pharmaceutical and biotech partners.

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eight partnerships are on record, tiered major, strategic and operational.

• Daiichi SankyomajorStrategic or Co-development Partner · 18 March 2026Leveragen announced collaboration with Daiichi Sankyo (TSE: 4568) to support development of advanced biologics using Leveragen's next-generation in vivo antibody discovery platforms. Daiichi Sankyo will leverage Leveragen's in vivo antibody discovery capabilities across selected research programs in multiple therapeutic areas. The collaboration aligns with Leveragen's strategy of partnering with leading pharmaceutical companies to apply its discovery platforms in early-stage research and preclinical development.
• Propeller BiomajorStrategic or Co-development Partner · 25 July 2025Strategic collaboration where Propeller Bio supports continued development of Leveragen's antibody discovery platforms through strategic investment. In return, Propeller gains access to Leveragen's full suite of proprietary antibody mouse models including Singularity Sapiens Mouse. Led by David Shen, former Founder/CEO of Proteologix (acquired by J&J for $850M).
• Cell Signaling TechnologymajorStrategic or Co-development Partner · 25 March 2025Comprehensive collaboration leveraging Leveragen's Singularity Musculus platform to expedite development of mouse-derived nanobodies tailored for reagent antibody applications. The partnership combines Leveragen's proprietary nanobody mouse technology with CST's expertise in high-quality research antibodies and reagents.
• Moonlight BiomajorStrategic or Co-development Partner · 29 January 2025Strategic collaboration integrating Leveragen's Singularity Sapiens Mouse platform with Moonlight Bio's T cell engineering expertise to develop cutting-edge T cell therapies for challenging cancers, particularly solid tumors. Leveragen spearheads discovery of fully human single-domain antibodies while Moonlight Bio oversees preclinical development of T cell therapies.
• DPBIO (Dapu Biotechnology)strategicTechnology or Integration · 12 December 2024Strategic partnership combining DPBIO's Cytospark droplet microfluidic single-B cell antibody discovery platform with Leveragen's Singularity Sapiens Mouse. The collaboration integrates technologies to overcome critical challenges in antibody discovery, with Leveragen retaining exclusive rights to resulting antibody IP and DPBIO entitled to use de-identified data to demonstrate its technology capabilities.
• Antibody SolutionsoperationalChannel Partner/ Reseller/ Distributor · 14 November 2024Antibody Solutions approved as contract research organization (CRO) for Leveragen's Singularity Sapiens Mouse platform. The agreement allows Antibody Solutions to pursue antibody discovery initiatives using Leveragen mice for clients who have licensed the proprietary platform, expanding the repertoire of human antibody-producing transgenic animals for client discovery programs.
• ModernamajorStrategic or Co-development Partner · 30 July 2024Multi-target research, option and license agreement where Leveragen employs its proprietary fully human single-domain antibody discovery platform to generate optimized binding modules against therapeutic targets selected by Moderna. Moderna has option to secure exclusive rights for subsequent development and commercialization. Leveragen receives undisclosed upfront payment, research funding, development/regulatory/commercial milestones, and tiered royalties on global sales.
• 92BiomajorOEM/ Whitelabel/ Licensing Partner · 28 May 2024Multi-target commercial license agreement utilizing Leveragen's Singularity Sapiens Mouse platform to facilitate creation of multi-specific antibodies and advanced therapeutics. 92Bio gains exclusive rights to develop and market antibodies produced using the platform. Leveragen receives upfront payments plus ongoing milestone payments and royalties on sales of developed therapies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: Public antibody discovery platform combining transgenic mice, single-cell screening, and AI to deliver lead antibodies to pharma partners. Directly comparable to Leveragen as a platform-licensing antibody discovery company serving large pharma with proprietary in vivo and in vitro technologies.
• Harbour BioMed: Develops the H2L2 and HCAb transgenic mouse platforms for fully human and heavy-chain-only antibody discovery, with therapeutic and platform licensing business models. Closely comparable to Leveragen in platform architecture (especially heavy-chain-only mice) and in offering platform licensing plus co-development; Leveragen's Hongjie Pan previously led programs at Harbour BioMed.
• Trianni Mouse (subsidiary of Alloy): Develops The Trianni Mouse, a transgenic human immunoglobulin locus platform for therapeutic antibody discovery. A direct competitor in the human-antibody-producing transgenic mouse space that Leveragen's Singularity Suite targets.
• Ablexis (AlivaMab Mouse): Develops the AlivaMab Mouse, a transgenic platform for fully human antibody discovery licensed to pharma and biotech. A direct peer in transgenic mouse antibody platforms competing for the same therapeutic discovery programs.
• Yumab (now part of Biotest/Polpharma Biologics): Offers antibody discovery using human antibody transgenic mouse platforms (e.g., OmniMab/HuMab) plus phage display and NGS workflows. Directly comparable as an integrated transgenic-mouse plus sequence-driven antibody discovery provider.
• Alloy Therapeutics: Provides a suite of antibody discovery platforms including transgenic mice (ATX-Gx, Bispecific, etc.) and discovery services to biotech and pharma. Directly comparable as a multi-platform antibody discovery licensor; Leveragen's Head of In Vitro Discovery, Brian O'Nuallain, previously led in vitro discovery at Alloy.

Emerging players

• Ginkgo Bioworks: Synthetic biology and cell engineering platform that hosts the Ginkgo Technology Network in which Leveragen participates. Comparable as a programmable biology platform that increasingly intersects with antibody engineering, although broader in scope than Leveragen's therapeutic focus.

Broad incumbents

• Kymab (acquired by Sanofi): Developed the IntelliSelect and Kymouse transgenic antibody discovery platforms, now part of Sanofi's antibody discovery infrastructure. Comparable as a transgenic antibody mouse platform licensed to pharma, now scaled inside a global biopharma.
• Distributed Bio (now part of Charles River): Antibody discovery services and platform including the SuperHuman and Tunable Fluorescent libraries. Comparable as an antibody discovery platform offering engineering and discovery services to pharma, now scaled within Charles River Laboratories.

Others

• AbCellera / TetraGenetics (ion channel platform, not antibody): Identified only as a relevant reference; AbCellera's main antibody platform is already listed at the top. No separate inclusion warranted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/leveragen
• Xx.com/leverageninc

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leveragen